Massar Capital Management’s Maravai LifeSciences MRVI Stock Holding History

Massar Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-200,000	Closed	-$650K	–	354
2025 Q4	$650K	Hold	200,000	–	–	0.07%	173
2025 Q3	$574K	Hold	200,000	–	–	0.08%	125
2025 Q2	$482K	Hold	200,000	–	–	0.36%	69
2025 Q1	$442K	Buy	+200,000	New	+$790K	0.49%	48

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Massar Capital Management's MRVI Position: Q1 2026 in Review

Massar Capital Management sold out of Maravai LifeSciences (MRVI) in Q1 2026, closing a stake of 200,000 shares — an estimated $650K sold.

Massar Capital Management first reported a position in MRVI in Q1 2025 and held it in 4 quarters. The position peaked at $650K in Q4 2025. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

Massar Capital Management reported no remaining Maravai LifeSciences position as of Q1 2026 after selling out during the quarter.
Massar Capital Management sold 200,000 Maravai LifeSciences shares in Q1 2026, an estimated $650K.
Massar Capital Management first reported a position in Maravai LifeSciences in Q1 2025 and held it in 4 quarters.
Massar Capital Management's Maravai LifeSciences position peaked at $650K in Q4 2025.
158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Massar Capital Management's 13F filing for Q1 2026, filed 15 May 2026.